< to news overview

Special Message from the Executive Board


The Immuno Valley Foundation will come to an end by 31 December 2018. In its 10 years of existence, Immuno Valley has been at the base of a unique public-private infrastructure in the field of inflammatory and infectious diseases in the Netherlands. Together with partners, a number of powerful partnerships have been established and Immuno Valley has played an important role in the setting up the Netherlands Antibiotic Development Platform, NADP. Important consortium management activities have also been carried out for Bac Vactory, 2RealGuts, and other projects.  We thank you for your interest over the past 10 years.


Dear Immuno Valley Partner and Network Member,

As many of you have noticed in the past period, important developments have taken place at the Immuno Valley Foundation. 

This year a new design of the partner compensation structure came into effect. Among other things, to increase the flexibility of the partners with regard to the Immuno Valley service activities. Together with partners, a number of powerful partnerships have been established and Immuno Valley has played an important role in the setting up the Netherlands Antibiotic Development Platform, NADP. Important consortium management activities have also been carried out for BacVactory, 2RealGuts, and other projects.

Strengthening the financial base of Immuno Valley was another important objective in 2018. However, these efforts have unfortunately not led to the extra boost that Immuno Valley needed to achieve a stable financial base. Event recent orientations into new forms of collaboration in order to guarantee continuity have not offered any new opportunities.

The negative result, despite the hard work, in combination with the departure of managing director, Liana Steeghs, and project manager, Mijke Vogels, has made the Executive Board decide to end the activities of the Immuno Valley Foundation by 31 December 2018. Agreements have been made with the coordinators of the current projects on the transfer of tasks. This consultation has also taken place for projects in the start-up phase.

In its 10 years of existence, Immuno Valley has been at the base of a unique public-private infrastructure in the field of inflammatory and infectious diseases in the Netherlands. As the Executive Board, and also on behalf of the Immuno Valley team, we would like to thank you for your dedication over the past 10 years and the impact this has brought. We wish you a future where innovation and collaboration will lead to new insights and, more importantly, to new products or therapies for humans and animals.

Sincerely,

on behalf of the Immuno Valley Executive Board

Dr. René M.L. Aerts
Chair